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fAUC may be useful. However, data are lacking 
on the marginal usefulness of the fAUC for pre-
dicting outcomes beyond that of the biomarkers 
that can already be captured during standard 
treatment monitoring, including MIC measure-
ments, in patients with tuberculosis. Ultimately, 
the Mycobacterium tuberculosis genome sequence 
may be found to adequately predict both MICs 
below the breakpoint and outcomes of treatment 
for tuberculosis and may provide a rapid and 
simple predictive tool.3,4
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Persistence of Zika Virus in Body Fluids — Final Report
To the Editor: Paz-Bailey and colleagues (Sept. 
27 issue)1 describe the dynamics of Zika virus 
(ZIKV) in body fluids in a cohort of participants 
who lived in an area where the virus was endem-
ic and in whom ZIKV infection was detected on 
reverse-transcriptase–polymerase-chain-reaction 
assay. We are concerned about the external valid-
ity of these results. First, the participants were 
enrolled in at least three hospital emergency de-
partments. Participants with arboviral infections 
who seek medical attention in an emergency de-
partment may have a more severe manifestation 
of the disease2 that may indicate a higher ZIKV 
RNA load in body fluids and a longer time until 
clearance than those who do not present to an 
emergency department.
Second, Puerto Rico continues to be an area 
where transmission of ZIKV and dengue virus 
occurs and where there is a high risk of ZIKV 
rechallenge through mosquito bites or sexual 
contact. The response to such a rechallenge in 
humans is unknown and should be considered 
to be a potential cause of persistence of detect-
able ZIKV RNA. In addition, previous dengue 
virus infection increases ZIKV replication or the 
viral load through antibody-dependent enhance-
ment mechanisms.3 Although the contribution of 
sexual transmission of ZIKV to the total number 
of cases of transmission is small,4 the dynamics 
of ZIKV may differ in vectorborne and sexually 
transmitted infections.5 All the aspects mentioned 
above limit the applicability of the results of this 
study to endemic areas where the rate of previ-
ous exposure to flaviviruses is similar to the rate 
in this study.
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The authors reply: In reply to Sánchez-Montalvá 
and colleagues: in contrast to dengue, which has 
a well-defined spectrum of severe disease, most 
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cases of noncongenital ZIKV disease are mild, 
except for rare complications such as Guillain–
Barré syndrome.1 In the participants in our study, 
the signs and symptoms were consistent with 
uncomplicated ZIKV disease. Furthermore, with 
respect to the duration of detectable ZIKV RNA, 
we saw no difference between the 35% of par-
ticipants who were enrolled at outpatient clinics 
and those who were enrolled at emergency depart-
ments (P = 0.22). We agree that it is not known 
whether humans can be reinfected with ZIKV; 
however, studies in mice have shown protection 
from reinfection, including an absence of detect-
able viremia.2 In vitro evidence of antibody-depen-
dent enhancement can occur in f laviviruses in 
the absence of in vivo evidence.3 A study from 
Colombia showed no evidence of in vivo enhance-
ment of ZIKV in patients with previous dengue 
virus infection.4 Moreover, findings in men from 
the continental United States, where dengue virus 
rarely circulates, were similar to those of our 
study.5 Finally, sexual transmission contributes 
to a small percentage of ZIKV infections and 
would not affect our findings.
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Acne Vulgaris
To the Editor: Zaenglein (Oct. 4 issue)1 notes that 
“in the United States, minocycline is the most 
commonly used antibiotic for acne, followed 
closely by doxycycline.” However, there is no evi-
dence that minocycline is superior to other anti-
biotics, including doxycycline, in the treatment 
of acne.2 Minocycline is associated with a broad-
er range of adverse events and a higher incidence 
of serious adverse events than doxycycline, and it 
may induce the potentially life-threatening drug 
reaction with eosinophilia and systemic symp-
toms syndrome.2-4 Because of its increased risk 
and the lack of evidence of greater benefit, mino-
cycline should not be prescribed before doxycy-
cline for acne treatment. In fact, the French Acne 
Guidelines Working Group does not recommend 
minocycline for acne treatment.5
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The author replies: In the United States, the 
use of antibiotics for the treatment of acne is in-
fluenced by many factors, including regional pre-
scribing differences and insurance coverage.1 In 
the past, a shortage of doxycycline hyclate and 
subsequent cost increases influenced by compet-
itive and noncompetitive market forces affected 
the prescribing of tetracyclines.2 Overall, as I noted 
in my article, minocycline in all its forms contin-
ues to be prescribed more often than doxycycline 
in the United States.2 My comment on trends in 
antibiotic usage for acne treatment in the United 
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